Earlier today, Vertex Pharmaceuticals (Nasdaq: VRTX) announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE